These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 17560332)

  • 1. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.
    Swanton C; Marani M; Pardo O; Warne PH; Kelly G; Sahai E; Elustondo F; Chang J; Temple J; Ahmed AA; Brenton JD; Downward J; Nicke B
    Cancer Cell; 2007 Jun; 11(6):498-512. PubMed ID: 17560332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CERTain role for ceramide in taxane-induced cell death.
    Kolesnick R; Altieri D; Fuks Z
    Cancer Cell; 2007 Jun; 11(6):473-5. PubMed ID: 17560328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.
    Lee AJ; Roylance R; Sander J; Gorman P; Endesfelder D; Kschischo M; Jones NP; East P; Nicke B; Spassieva S; Obeid LM; Birkbak NJ; Szallasi Z; McKnight NC; Rowan AJ; Speirs V; Hanby AM; Downward J; Tooze SA; Swanton C
    J Pathol; 2012 Feb; 226(3):482-94. PubMed ID: 21953249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
    Chabalier C; Lamare C; Racca C; Privat M; Valette A; Larminat F
    Cell Cycle; 2006 May; 5(9):1001-7. PubMed ID: 16639080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.
    Lee EA; Keutmann MK; Dowling ML; Harris E; Chan G; Kao GD
    Mol Cancer Ther; 2004 Jun; 3(6):661-9. PubMed ID: 15210851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
    Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
    Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
    Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
    Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
    Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
    J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
    Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
    Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
    [No Abstract]   [Full Text] [Related]  

  • 11. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
    Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
    PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
    Lee J; Gollahon L
    Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest.
    Baek KH; Shin HJ; Yoo JK; Cho JH; Choi YH; Sung YC; McKeon F; Lee CW
    J Leukoc Biol; 2003 Jun; 73(6):850-61. PubMed ID: 12773518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
    Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
    J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].
    Huang L; Zhang QH; Ao QL; Xing H; Lu YP; Ma D
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):96-100. PubMed ID: 17645840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.
    Sudo T; Nitta M; Saya H; Ueno NT
    Cancer Res; 2004 Apr; 64(7):2502-8. PubMed ID: 15059905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
    Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
    Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.
    Castilla C; Flores ML; Medina R; Pérez-Valderrama B; Romero F; Tortolero M; Japón MA; Sáez C
    Mol Cancer Ther; 2014 Oct; 13(10):2372-83. PubMed ID: 25122070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
    Talekar M; Ouyang Q; Goldberg MS; Amiji MM
    Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.